Equities

Financiere de Tubize SA

Financiere de Tubize SA

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (EUR)130.80
  • Today's Change0.600 / 0.46%
  • Shares traded27.58k
  • 1 Year change+87.66%
  • Beta0.6433
Data delayed at least 15 minutes, as of Sep 19 2024 16:20 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of EUR
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments0.571.0716
Total Receivables, Net00.000.00
Total Inventory------
Prepaid expenses------
Other current assets, total0.060.050.03
Total current assets0.641.1216
Property, plant & equipment, net------
Goodwill, net------
Intangibles, net------
Long term investments1,9201,8381,743
Note receivable - long term------
Other long term assets------
Total assets1,9201,8391,759
LIABILITIES
Accounts payable0.260.200.47
Accrued expenses------
Notes payable/short-term debt000
Current portion long-term debt/capital leases794820
Other current liabilities, total443934
Total current liabilities1248754
Total long term debt000
Total debt794820
Deferred income tax------
Minority interest------
Other liabilities, total------
Total liabilities1248754
SHAREHOLDERS EQUITY
Common stock235235235
Additional paid-in capital1.221.221.22
Retained earnings (accumulated deficit)1,5601,5151,468
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.460.460.46
Total equity1,7971,7521,705
Total liabilities & shareholders' equity1,9201,8391,759
Total common shares outstanding454545
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.